Diagnosis and Treatment of Atypical HLA-B27 Associated Uveitis
Diagnostic Considerations
- The combination of granulomatous uveitis with HLA-B27 positivity should raise concern for misdiagnosis or masquerade syndrome, such as malignancy or infection, and requires immediate reassessment of the diagnosis 1, 2
- Before proceeding with treatment, it is essential to rule out infections and masquerade syndromes through diagnostic vitrectomy, cerebrospinal fluid cytology, and brain MRI if indicated 1, 2
Initial Treatment Approach
- The American Academy of Ophthalmology recommends topical corticosteroids as first-line treatment for HLA-B27 associated anterior uveitis, which is typically episodic and self-limiting 3, 4
- Topical prednisolone should be started with cycloplegics, and its use should be limited to ≤3 months due to the significant risk of elevated intraocular pressure and cataract formation 3, 4
Monitoring and Escalation to Systemic Therapy
- Patients with controlled uveitis on stable therapy should be monitored every 3 months 3, 4
- The American College of Rheumatology recommends screening for latent or active tuberculosis, HIV, and hepatitis before initiating systemic immunomodulatory therapy 2, 4
- Methotrexate is the recommended first-line systemic agent for refractory non-infectious uveitis, with a dose of 0.5-1 mg/kg/week, maximum 30 mg 4
Special Considerations
- The American Academy of Ophthalmology recommends avoiding etanercept in HLA-B27 associated uveitis due to the risk of severe, atypically chronic bilateral uveitis with cystoid macular edema 4
- If a patient is not responding adequately to therapy, it is essential to rule out treatment nonadherence, infections, and masquerade syndromes before considering dose escalation or transitioning to alternative agents 1, 2, 6
Associated Systemic Disease Evaluation
- The American College of Rheumatology recommends referring patients to rheumatology if they have inflammatory back pain, morning stiffness, or a family history of spondyloarthritis 7, 5
- First-line treatment for associated spondyloarthritis is NSAIDs at full dose, according to the American College of Rheumatology 7, 5